Helen M Collins, L Sophie Gullino, Dersu Ozdemir, Caroline Lazarenco, Yulia Sudarikova, Elizabeth Daly, Fuencisla Pilar Cuéllar, Raquel Pinacho, David M Bannerman, Trevor Sharp
Cessation of therapy with a selective serotonin (5-HT) reuptake inhibitor (SSRI) is often associated with an early onset and disabling discontinuation syndrome, the mechanism of which is surprisingly little investigated. Here we determined the effect on 5-HT neurochemistry of discontinuation from the SSRI paroxetine. Paroxetine was administered repeatedly to mice (once daily, 12 days versus saline controls) and then either continued or discontinued for up to 5 days. Whereas brain tissue levels of 5-HT and/or its metabolite 5-HIAA tended to decrease during continuous paroxetine, levels increased above controls after discontinuation, notably in hippocampus...
April 12, 2024: Neuropsychopharmacology